This Pot Stock’s Sales Were up 870% Last Quarter!

Why Canopy Growth Corp (TSX:WEED)(NYSE:CGC) may no longer be the hottest pot stock to invest in.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

When it comes to pot stocks, the name of the game is sales growth. With estimates for the industry continuing to get bigger as more countries legalize marijuana, there’s a lot of excitement around cannabis companies and competition is becoming fierce. A good example is Canopy Growth (TSX:WEED)(NYSE:CGC), which has grown by more than 400% in just two years.

However, the one negative against the stock is that with a market cap of more than $20 billion, the opportunity for investors might be fleeting. A lot of the upside may have already been realized, as the company is already partnered with a big beverage maker, and its sales have already seen a lot of growth. In its most recent quarter, Canopy Growth’s sales reached $83 million, which was nearly quadruple the $22 million that the company generated a year ago.

Although profits remain inconsistent, that hasn’t deterred investors, as the hype around one of the most iconic pot stocks in the world hasn’t let up. And there still might be a lot more bullishness around the corner, as Canopy Growth is looking to expand south of the border now that the farm bill has passed. But as good as Canopy Growth has done lately, there might be a lot more potential elsewhere.

MedMen Enterprises (CNSX:MMEN) trades on the Canadian exchange, but it’s very much a U.S. company, and one with significant potential. While it’s a lot smaller than Canopy Growth in size, that doesn’t mean it’s not a threat. The company has already grabbed a significant share of the market. In its most recent quarterly results, MedMen’s sales reached around US$30 million, which is nearly 10 times the US$3 million it generated just one year ago.

It’s an amazing growth story for a company that’s proven to be popular among consumers with its modern, spacious stores that make you think you’re in an Apple store. With prime retail locations, MedMen has been able to differentiate itself from many of its competitors, and that’s very important at a time when there are a lot of cannabis companies popping up.

While MedMen has operations in several U.S. states, it’s been California that’s been responsible for a lot of its growth. With recreational cannabis sales commencing at the start of 2018, it’s been a fairly new market for cannabis companies to get access to. For MedMen, US$23.7 million of its sales came from the Golden State, representing the majority of the company’s sales for the quarter.

The downside, however, is that the company’s expenses have soared, as MedMen incurred a loss of US$19 million during the quarter. A big challenge for many marijuana companies has been keeping costs down amid such rapid growth and expansion. While over time we would expect to see some efficiencies and cost savings to be gained, in the near term it’ll be difficult for companies to stay out of the red.

MedMen is an intriguing investment today that could have a lot more upside than Canopy Growth, but it might come with a bit more risk as well.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. David Gardner owns shares of Apple. The Motley Fool owns shares of Apple and has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple.

More on Cannabis Stocks

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »